NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

Item

http://www.wikidata.org/entity/Q36809405

Q36809405

about

Impact of New Genomic Technologies on Understanding Adverse Drug Reactions PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 Isoniazid metabolism and hepatotoxicity Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis Pharmacogenetics in Jewish populations.Pharmacogenomics of antimicrobial agents.Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Future of pharmacogenetics-based therapy for tuberculosis.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.Optimizing the clinical pharmacology of tuberculosis medications.The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury.Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.The challenges of pharmacokinetic variability of first-line anti-TB drugs.A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes.A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.The Role of N-Acetyl Transferases on Isoniazid Resistance from Mycobacterium tuberculosis and Human: An In Silico Approach.A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review."Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis.NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity.Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients.Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?PharmGKB summary: isoniazid pathway, pharmacokinetics.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Benefit of treatment of latent tuberculosis infection in individual patients.Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.Determination of NAT2 acetylation status in the Greenlandic population.Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.Pharmacogenetics in Africa, an Opportunity for Appropriate Drug Dosage Regimens: on the Road to Personalized Healthcare.

P2860

Q26787099-7268C8E8-E998-488A-8F25-9722C3B32C34 Q27011622-44F9174B-50B6-4A75-B756-3CD6F8C4E9BB Q28076859-BE396DAE-6282-4060-8765-B3C16ECCC477 Q28079207-0A4C11E2-E0B8-40A2-909F-7B8316CE548D Q28550148-1B1ECABE-727A-4FD5-B17C-0BC807D01F27 Q28553471-0707B00D-1ACA-4A5B-81EB-4ED6A21C5CDA Q33768531-4D159D74-1A07-468C-9184-C20B4B09D37A Q34458720-EFDFCDC6-3178-40A5-86DB-9F589021CF74 Q34977413-E73A6B82-A625-4846-85EE-C908F2044F3A Q34986858-A24610F9-211B-4E6C-A12B-7474E8AD49F1 Q35867681-2E12E122-97CB-41DA-BAB2-1568E01379E5 Q35934555-13722A8C-4458-47FD-8556-FEB1AA33C200 Q36158322-45F79222-8165-4395-A891-6F1F2B2D8F80 Q36439129-FC0A6E72-6CD1-4E44-BE31-805DACB057E9 Q37287701-29633C93-3C3C-4D58-A2B6-F9333D4D162A Q38209573-166B6FD6-CFED-4065-B38C-2788CFF26BB2 Q38213320-6DF1D5F0-DB44-4AA7-AD91-2199826530EC Q38391340-0D555450-3464-40F8-A9A3-390F6D594343 Q38542159-75476593-C129-441C-A0AA-26B006AD6DE6 Q38651282-BC421083-1903-459A-92B8-938F3AA33563 Q38803026-FA71E613-0EA5-40B3-98DC-0AC5C9E2FDBA Q38865905-7A37925D-5A94-4390-8B09-A605C8D2E574 Q38977166-8F182675-9689-4B7E-B6B7-C906E9769B04 Q40592548-E22918D4-9653-42D2-AF6E-A26FACEE4BDB Q41068782-E8BCFCE0-9015-4012-A89E-C8705EBA854E Q41102009-269FEA85-4C09-4F82-A53A-C29D7545B180 Q41124264-8580B654-01BE-4413-92FC-7DC5D8FF5AF4 Q41238712-329684A4-59DF-4C66-9475-3479E6A7C943 Q41611314-93A35916-03DF-484A-A8E9-5D6549833AF0 Q41660660-9C0FFA48-601E-4903-B5AA-F26FAD862B2B Q41675062-D65FFDF7-369E-4832-AD73-1DE0F1AFE265 Q41679231-CDD09E56-9AE1-4315-8B12-9C1D3729FBAA Q41875502-E7D0A116-7B10-4A4A-83A6-54BCB49887BF Q42090708-3855F28D-A92D-4B43-BF0A-4C3E6195147B Q42335970-CAD429BA-6EF4-48C2-85A6-39383E59332F Q42364683-C0620312-FE4A-4BA2-BA2A-65A6E3E6C8B8 Q42696912-DF5C7434-9D97-4968-86CB-EABDFB34014A Q42702218-946F6070-AF17-4473-BBCB-098E6218BDDB Q45046059-93DE5FD4-4F17-43B9-AE98-DD1BE0E998E1 Q45920621-D83DF8AB-40E2-465F-A81D-861012D9D298

P2860

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

Item

http://www.wikidata.org/entity/Q36809405

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

NAT2 genotype guided regimen r ...... pharmacogenetics-based therapy

@ast

NAT2 genotype guided regimen r ...... pharmacogenetics-based therapy

@en

type

Item

label

NAT2 genotype guided regimen r ...... pharmacogenetics-based therapy

@ast

NAT2 genotype guided regimen r ...... pharmacogenetics-based therapy

@en

prefLabel

NAT2 genotype guided regimen r ...... pharmacogenetics-based therapy

@ast

NAT2 genotype guided regimen r ...... pharmacogenetics-based therapy

@en

P1476

NAT2 genotype guided regimen r ...... pharmacogenetics-based therapy

@en

P2093

Ichiro Kawase

http://www.w3.org/2001/XMLSchema#string

Junichi Azuma

http://www.w3.org/2001/XMLSchema#string

Kazunari Tsuyuguchi

http://www.w3.org/2001/XMLSchema#string

Masako Ohno

http://www.w3.org/2001/XMLSchema#string

Pharmacogenetics-based tuberculosis therapy research group

http://www.w3.org/2001/XMLSchema#string

Ryuji Kubota

http://www.w3.org/2001/XMLSchema#string

Sayaka Kamimura

http://www.w3.org/2001/XMLSchema#string

Soichiro Yokota

http://www.w3.org/2001/XMLSchema#string

Takayuki Nagai

http://www.w3.org/2001/XMLSchema#string

Tetsuya Takashima

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

N-acetyltransferase

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Toxic hepatitis with isoniazid and rifampin. A meta-analysis.

Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.

Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

P2888

s00228-012-1429-9

P304

1091-1101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-012-1429-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233411733

http://www.w3.org/2001/XMLSchema#string

P698

23150149

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3641305

http://www.w3.org/2001/XMLSchema#string

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

about

P2860

P2860

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932